<DOC>
	<DOCNO>NCT02630706</DOCNO>
	<brief_summary>This study evaluate efficacy safety addition ertugliflozin metformin monotherapy Asian participant Type 2 diabetes mellitis ( T2DM ) inadequate glycemic control metformin monotherapy . The primary hypothesis mean reduction baseline hemoglobin A1C ( HbA1C ) 15 mg 5 mg ertugliflozin great placebo .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Ertugliflozin Asian Participants With Type 2 Diabetes Inadequate Glycemic Control Metformin Monotherapy</brief_title>
	<detailed_description>This study include 1-week screening period , 8-week ( great ) antihyperglycemic agent ( AHA ) wash-off and/or metformin dose stable period , 2-week single-blind placebo run-in period , 26-week double-blind treatment period , post-treatment telephone contact 14 day last dose study drug .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Asian participant ≥18 year age time initial Screening . Type 2 diabetes mellitus per American Diabetes Association guideline . Metformin monotherapy ( ≥1500 mg/day ) initial Screening A1C 7.010.5 % ( 5391 mmol/mol ) OR metformin monotherapy ( &lt; 1500 mg/day ) initial Screening A1C 7.511.0 % ( 5897 mmol/mol ) OR dual combination therapy metformin + sulfonylurea , DDP4 inhibitor , meglitinide , alphaglucosidase inhibitor initial Screening A1C 6.59.5 % ( 4880 mmol/mol ) . Body mass index ( BMI ) ≥18.0 kg/m^2 . Male female reproductive potential . Female reproductive potential agrees remain abstinent heterosexual activity use 2 acceptable combination contraception . History type 1 diabetes mellitus history ketoacidosis . History specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrinopathies , drug chemicalinduced , postorgan transplant . ) History myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study start . Active , obstructive uropathy indwell urinary catheter . History malignancy ≤5 year prior study start , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week engages binge drink . Any clinically significant malabsorption condition . Is weightloss program weightloss medication medication associate weight change weight stable prior study start . Has undergone bariatric surgery within past 12 month &gt; 12 month weight stable prior study start . A known hypersensitivity intolerance sodium glucose cotransporter ( SGLT2 ) inhibitor . On previous clinical study ertugliflozin . Is take blood pressure lipid alter medication stable dose least 4 week prior study start . Current treatment hyperthyroidism . On thyroid replacement therapy stable dose least 6 week prior study start . A medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease . Has treat follow agent within 12 week study start prerandomization period : Insulin type ( except shortterm use concomitant illness stress ) , injectable antihyperglycemic agent ( e.g. , pramlintide , exenatide , liraglutide ) , another SGLT2 inhibitor , bromocriptine , colesevelam , rosiglitazone pioglitazone , AHA exception protocolapproved agent . Is likely require treatment ≥14 consecutive day repeat course pharmacologic dos corticosteroid . Has undergone surgical procedure within 6 week prior study start plan major surgery study . Pregnant breastfeeding , plan conceive trial , include 14 day follow last dose study medication . Planning undergo hormonal therapy preparation egg donation trial , include 14 day follow last dose study medication . Donated blood blood product within 6 week study start . Has Human Immunodeficiency Virus ( HIV ) . Has blood dyscrasia disorder cause hemolysis unstable red blood cell . Has clinically important hemotological disorder ( aplastic anemia , myeloproliferative myelodyplastic syndrome , thrombocytopenia . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>